Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B48e8e96d92f4e315151430186c607060> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B48e8e96d92f4e315151430186c607060 NCIT_P378 "NCI" @default.
- B48e8e96d92f4e315151430186c607060 type Axiom @default.
- B48e8e96d92f4e315151430186c607060 annotatedProperty IAO_0000115 @default.
- B48e8e96d92f4e315151430186c607060 annotatedSource NCIT_C80046 @default.
- B48e8e96d92f4e315151430186c607060 annotatedTarget "A whole cell melanoma cancer vaccine with potential immunostimulating and antineoplastic activities. B16alphaGal melanoma vaccine contains three types of human melanoma cell lines that are genetically engineered to express the alpha(1,3)-galactosyl (alphaGal) epitope on cell surfaces. The agent stimulates a hyperacute rejection of whole melanoma cancer cells expressing alphaGal epitopes, initiated by opsonization by anti-alphaGal antibodies and followed by antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis. This results in the stimulation of a broader cytotoxic T-lymphocyte response (CTL) directed against tumor antigens on melanoma cells that do not express alphaGal. AlphaGal is not normally expressed in humans because alpha(1,3)-galactosyltransferase (Alpha-GT), the enzyme that catalyzes the synthesis of alphaGal epitopes on glycoproteins and glycolipids, is not naturally present in humans and other primates." @default.